ATE456380T1 - Hypoxie-induzierbares vegf plasmid für ischämische erkrankung - Google Patents

Hypoxie-induzierbares vegf plasmid für ischämische erkrankung

Info

Publication number
ATE456380T1
ATE456380T1 AT04713771T AT04713771T ATE456380T1 AT E456380 T1 ATE456380 T1 AT E456380T1 AT 04713771 T AT04713771 T AT 04713771T AT 04713771 T AT04713771 T AT 04713771T AT E456380 T1 ATE456380 T1 AT E456380T1
Authority
AT
Austria
Prior art keywords
ischemic disease
hypoxia
vegf
plasmids
inducable
Prior art date
Application number
AT04713771T
Other languages
English (en)
Inventor
Minhyung Lee
Sung Kim
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Application granted granted Critical
Publication of ATE456380T1 publication Critical patent/ATE456380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT04713771T 2003-02-21 2004-02-23 Hypoxie-induzierbares vegf plasmid für ischämische erkrankung ATE456380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44896103P 2003-02-21 2003-02-21
PCT/US2004/005372 WO2004076633A2 (en) 2003-02-21 2004-02-23 Hypoxia inducible vegf plasmid for ischemic disease

Publications (1)

Publication Number Publication Date
ATE456380T1 true ATE456380T1 (de) 2010-02-15

Family

ID=32927484

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04713771T ATE456380T1 (de) 2003-02-21 2004-02-23 Hypoxie-induzierbares vegf plasmid für ischämische erkrankung

Country Status (9)

Country Link
US (2) US7638322B2 (de)
EP (1) EP1594549B1 (de)
JP (1) JP4652325B2 (de)
KR (1) KR101077689B1 (de)
AT (1) ATE456380T1 (de)
CA (1) CA2516727C (de)
DE (1) DE602004025328D1 (de)
ES (1) ES2339113T3 (de)
WO (1) WO2004076633A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ553162A (en) 2004-08-16 2010-03-26 Quark Biotech Inc Double stranded siRNA compounds that inhibit RRTP801
UY30097A1 (es) 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
WO2008106102A2 (en) 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104973A1 (en) * 1997-08-21 2003-06-05 Quark Biotech, Inc. Hypoxia-regulated genes
US6548633B1 (en) * 1998-12-22 2003-04-15 Genset, S.A. Complementary DNA's encoding proteins with signal peptides

Also Published As

Publication number Publication date
WO2004076633A3 (en) 2005-06-02
US7638322B2 (en) 2009-12-29
US20110015257A1 (en) 2011-01-20
EP1594549B1 (de) 2010-01-27
JP2006518604A (ja) 2006-08-17
JP4652325B2 (ja) 2011-03-16
CA2516727A1 (en) 2004-09-10
DE602004025328D1 (de) 2010-03-18
EP1594549A4 (de) 2008-01-23
KR101077689B1 (ko) 2011-10-27
ES2339113T3 (es) 2010-05-17
CA2516727C (en) 2014-02-04
WO2004076633A2 (en) 2004-09-10
US7998941B2 (en) 2011-08-16
EP1594549A2 (de) 2005-11-16
KR20050103302A (ko) 2005-10-28
US20070149467A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
ES2652595T3 (es) Lactonas de sesquiterpeno tricíclico para el uso en el tratamiento de la obesidad y enfermedades relacionadas y condiciones tratables no terapéuticas
AR039985A1 (es) Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
MX2007000028A (es) Derivados de nicotinamida y su uso como agentes terapeuticos.
TW200626138A (en) Heterocyclic derivatives and their use as therapeutic agents
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
TW200806318A (en) Uses of anti-insulin-like growth factor I receptor antibodies
RU95120403A (ru) Стимулятор эндогенной продукции цитокинов и гемопоэтических факторов и способ его использования
NZ701205A (en) Optimised subcutaneous therapeutic agents
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
UA86400C2 (ru) Применение эритропоэтина в низком дозировании для пациентов с дисфункцией эндотелиальных клеток-предшественников, сердечно-сосудистым фактором риска и повреждением конечного органа
ATE543492T1 (de) Behandlung von lungenkrebs
NZ515891A (en) New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents
JP2010538020A5 (de)
GEAP202516706A (en) Cyclic peptides for trapping interleukin-1 beta
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
EP1594549A4 (de) Hypoxie-induzierbares vegf plasmid für ischämische erkrankung
NO20055692L (no) Intravenos injeksjon av ikkeneurotoksiske plasminogenaktivatorer til behandling av cerebralt slag
WO2004004664A3 (en) Methods for treating or preventing ischemic injury
MX2022012001A (es) Tratamiento preventivo de la migra?a.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
Crossman et al. Bradykinin induced wheal and flare is not mediated by histamine release or cyclooxygenase products.
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties